HPV Genotype Specific and Age Stratified Immediate Prevalence of Cervical Precancers and Cancers in Women with NILM/hrHPV+: A Single Center Retrospective Study of 26,228 Cases

References

• ArbynM, WeiderpassE, BruniL, de SanjoseS, SaraiyaM, FerlayJ. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191–e203. doi:10.1016/S2214-109X(19)30482-631812369
   PubMed Web of Science ®Google Scholar
• WalboomersJM, JacobsMV, ManosMM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19. doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F10451482
   PubMed Web of Science ®Google Scholar
• VinokurovaS, WentzensenN, KrausI, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008;68:307–313. doi:10.1158/0008-5472.CAN-07-275418172324
   PubMed Web of Science ®Google Scholar
• MoodyCA, LaiminsLA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10:550–560. doi:10.1038/nrc288620592731
   PubMed Web of Science ®Google Scholar
• McLaughlin-DrubinME, MungerK. Biochemical and functional interactions of human papillomavirus proteins with polycomb group proteins. Viruses. 2013;5:1231–1249. doi:10.3390/v505123123673719
   PubMed Web of Science ®Google Scholar
• PerkinsRB, GuidoRS, CastlePE, et al. Committee AR-BMCG: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020;24:102–131. doi:10.1097/LGT.000000000000052532243307
   PubMed Web of Science ®Google Scholar
• NauclerP, RydW, TornbergS, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357:1589–1597. doi:10.1056/NEJMoa07320417942872
   PubMed Web of Science ®Google Scholar
• FranceschiS, DennyL, IrwinKL, et al. Eurogin 2010 roadmap on cervical cancer prevention. Int J Cancer. 2011;128(12):2765–2774. doi:10.1002/ijc.2591521207409
   PubMed Web of Science ®Google Scholar
• AbrahamJ, StengerM. Cobas HPV test for first-line screening for cervical cancer. J Community Support Oncol. 2014;12:156–157. doi:10.12788/jcso.003924971425
   PubMedGoogle Scholar
• WangJ, DuY, DongJ, et al. Clinical significance of genotyping for human papillomavirus (HPV) 16 18/45 combined with cytology in cervical exfoliated cells in HPV oncogenic mRNA-positive women. Gynecol Oncol. 2019;153:34–40. doi:10.1016/j.ygyno.2018.12.02830630629
   PubMed Web of Science ®Google Scholar
• BenevoloM, Giorgi-RossiP. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. Cancer Cytopathol. 2014;122:76. doi:10.1002/cncy.2136024170415
   PubMed Web of Science ®Google Scholar
• HaedickeJ, IftnerT. A review of the clinical performance of the Aptima HPV assay. J Clin Virol. 2016;76(Suppl 1):S40–S8. doi:10.1016/j.jcv.2015.10.02726614686
   PubMed Web of Science ®Google Scholar
• BenevoloM, VocaturoA, CaraceniD, et al. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol. 2011;49:2643–2650. doi:10.1128/JCM.02570-1021525231
   PubMed Web of Science ®Google Scholar
• RatnamS, CoutleeF, FontaineD, et al. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol. 2010;48:2779–2785. doi:10.1128/JCM.00382-1020573862
   PubMed Web of Science ®Google Scholar
• ArbynM, RoelensJ, CuschieriK, et al. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer. 2013;132:101–108. doi:10.1002/ijc.2763622610699
   PubMed Web of Science ®Google Scholar
• ArbynM, RoncoG, AnttilaA, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(Suppl 5):F88–F99. doi:10.1016/j.vaccine.2012.06.09523199969
   PubMed Web of Science ®Google Scholar
• VerdoodtF, SzarewskiA, HalfonP, CuschieriK, ArbynM. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. Cancer Cytopathol. 2013;121:675–687. doi:10.1002/cncy.2132523881840
   PubMed Web of Science ®Google Scholar
• NievesL, EnersonCL, BelinsonS, et al. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection. Int J Gynecol Cancer. 2013;23(3):513–518. doi:10.1097/IGC.0b013e318280f3bc23334437
   PubMed Web of Science ®Google Scholar
• RijkaartDC, HeidemanDA, CoupeVM, et al. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology. J Clin Microbiol. 2012;50:2390–2396. doi:10.1128/JCM.06587-1122553244
   PubMed Web of Science ®Google Scholar
• ArgyriE, TsimplakiE, DaskalopoulouD, StravopodisDJ, KouikoglouO, TerzakisE. E6/E7 mRNA expression of high-risk HPV types in 849 Greek women. Anticancer Res. 2013;33:4007–4011.24023342
   PubMed Web of Science ®Google Scholar
• DuvlisS, Popovska-JankovicK, ArsovaZS, MemetiS, PopeskaZ, Plaseska-KaranfilskaD. HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women. J Med Virol. 2015;87:1578–1586. doi:10.1002/jmv.2419925880030
   PubMed Web of Science ®Google Scholar
• HanM, LiJ, AustinM, VarmaKR, ZhangH. Human Papillomavirus (HPV) 16 and 18/45 genotyping-directed follow-up of women with messenger RNA HPV-positive, cytology-negative cervical screening test results. Am J Clin Pathol. 2020;153:243–250. doi:10.1093/ajcp/aqz15631603212
   PubMed Web of Science ®Google Scholar
• KitchenerHC, AlmonteM, ThomsonC, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10:672–682. doi:10.1016/S1470-2045(09)70156-119540162
   PubMed Web of Science ®Google Scholar
• RoncoG, Giorgi-RossiP, CarozziF, et al. New technologies for cervical cancer screening working G: efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249–257. doi:10.1016/S1470-2045(09)70360-220089449
   PubMed Web of Science ®Google Scholar
• RijkaartDC, BerkhofJ, RozendaalL, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13:78–88. doi:10.1016/S1470-2045(11)70296-022177579
   PubMed Web of Science ®Google Scholar
• CoxJT, CastlePE, BehrensCM, SharmaA, WrightTCJr, CuzickJ. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013;208(184):e1–e11. doi:10.1016/j.ajog.2012.11.020
   PubMed Web of Science ®Google Scholar
• ReidJL, WrightTCJr, StolerMH, et al. Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study. Am J Clin Pathol. 2015;144(3):473–483. doi:10.1309/AJCPHVD7MIP3FYVV26276778
   PubMed Web of Science ®Google Scholar
• CuzickJ, CadmanL, MesherD, et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer. 2013;108:908–913. doi:10.1038/bjc.2013.2223370211
   PubMed Web of Science ®Google Scholar
• SzarewskiA, MesherD, CadmanL, et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol. 2012;50:1867–1873. doi:10.1128/JCM.00181-1222422852
   PubMed Web of Science ®Google Scholar
• OvestadIT, VennestromU, AndersenL, et al. Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol Oncol. 2011;123:278–283. doi:10.1016/j.ygyno.2011.07.02421835440
   PubMed Web of Science ®Google Scholar
• CastlePE, EatonB, ReidJ, GetmanD, DockterJ. Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology. J Clin Microbiol. 2015;53:1277–1281. doi:10.1128/JCM.03558-1425653409
   PubMed Web of Science ®Google Scholar
• BinnickerMJ, PrittBS, DureskoBJ, et al. Comparative evaluation of three commercial systems for detection of high-risk human papillomavirus in cervical and vaginal ThinPrep PreservCyt samples and correlation with biopsy results. J Clin Microbiol. 2014;52:3763–3768. doi:10.1128/JCM.01928-1425122861
   PubMed Web of Science ®Google Scholar
• SongJS, KimEJ, ChoiJ, GongG, SungCO. Significance of HPV-58 infection in women who are HPV-positive, cytology-negative and living in a country with a high prevalence of HPV-58 infection. PLoS One. 2013;8(3):e58678. doi:10.1371/journal.pone.005867823505548
   PubMed Web of Science ®Google Scholar
• TaoX, ZhangH, LiJ, et al. Prevalence of HPV-16/18 genotypes and immediate histopathologic correlation results in a Chinese population with negative cytology and positive high-risk HPV testing. Cancer Cytopathol. 2019;127:650–657. doi:10.1002/cncy.2218031532582
   PubMed Web of Science ®Google Scholar
• WIICoHPV, CervicalC. HPV and cervical cancer in the 2007 report. Vaccine. 2007;25(Suppl 3):C1–C230.18068032
   PubMedGoogle Scholar
• ReboljM, BondeJ, PreislerS, EjegodD, RygaardC. Human papillomavirus assays and cytology in primary cervical screening of women aged 30 years and above. PLoS One. 2016;11:e0147326. doi:10.1371/journal.pone.014732626789267
   PubMed Web of Science ®Google Scholar
• IftnerT, BeckerS, NeisKJ, et al. Head-to-head comparison of the RNA-based Aptima Human Papillomavirus (HPV) assay and the DNA-based Hybrid Capture 2 HPV test in a routine screening population of women aged 30 to 60 years in Germany. J Clin Microbiol. 2015;53:2509–2516. doi:10.1128/JCM.01013-1526019212
   PubMed Web of Science ®Google Scholar
• de SanjoseS, QuintWG, AlemanyL, et al.; Group HPVTTS. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–1056. doi:10.1016/S1470-2045(10)70230-820952254
   PubMed Web of Science ®Google Scholar
• KumarN, GuptaR, GuptaS. Glandular cell abnormalities in cervical cytology: what has changed in this decade and what has not?Eur J Obstet Gynecol Reprod Biol. 2019;240:68–73. doi:10.1016/j.ejogrb.2019.06.00631234059
   PubMed Web of Science ®Google Scholar
• KirschnerB, SimonsenK, JungeJ. Comparison of conventional Papanicolaou smear and SurePath liquid-based cytology in the Copenhagen population screening programme for cervical cancer. Cytopathology. 2006;17:187–194. doi:10.1111/j.1365-2303.2006.00384.x16879266
   PubMed Web of Science ®Google Scholar
• BurnleyC, DuddingN, ParkerM, ParsonsP, WhitakerCJ. Glandular neoplasia and borderline endocervical reporting rates before and after conversion to the SurePath(TM) liquid-based cytology (LBC) system. Diagn Cytopathol. 2011;39:869–874. doi:10.1002/dc.2147122081523
   PubMed Web of Science ®Google Scholar
• KituncharoenS, TantbirojnP, NiruthisardS. Comparison of unsatisfactory rates and detection of abnormal cervical cytology between conventional papanicolaou smear and liquid-based cytology (Sure Path(R). Asian Pac J Cancer Prev. 2015;16:8491–8494. doi:10.7314/APJCP.2015.16.18.849126745107
   PubMedGoogle Scholar
• BudakMS, SenturkMB, KayaC, et al. A comparative study of conventional and liquid-based cervical cytology. Ginekol Pol. 2016;87:190–193. doi:10.17772/gp/6098027306127
   PubMed Web of Science ®Google Scholar
• FischerG, CormierK. Glandular Cell Abnormalities on SurePath preparations: a retrospective review with cytology-histology correlations. Acta Cytol. 2018;62(5–6):423–429. doi:10.1159/00049300030244241
   PubMed Web of Science ®Google Scholar
• MoscickiAB, CoxJT. Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis. 2010;14:73–80. doi:10.1097/LGT.0b013e3181cec41120043357
   PubMed Web of Science ®Google Scholar
• SchiffmanM, RodriguezAC. Heterogeneity in CIN3 diagnosis. Lancet Oncol. 2008;9:404–406. doi:10.1016/S1470-2045(08)70110-418452848
   PubMed Web of Science ®Google Scholar
• McCredieMR, SharplesKJ, PaulC, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9:425–434. doi:10.1016/S1470-2045(08)70103-718407790
   PubMed Web of Science ®Google Scholar